Claudine Bruck
Vermogen: 35 864 $ op 31-08-2026
Vermogen: 35 864 $ op 31-08-2026
Claudine E.
Bruck was the founder of Prolifagen, Inc., founded in 2016, where the title held was Chief Executive Officer from 2016 to 2022.
Current jobs include Independent Director at Annovis Bio, Inc. since 2015, Director at Ophidion, Inc., Course Director at Institute For Translational Medicine & Therapeutics, and Chief Scientific Officer at SapVax LLC.
Former jobs include Independent Director at Navidea Biopharmaceuticals, Inc. from 2018 to 2021, Course Director at the University of Pennsylvania, Vice President & Head-Biology at Center of Excellence For External Drug Discovery from 2005 to 2008, Head-Cancer Vaccine Program at GlaxoSmithKline LLC, and Assistant Professor at Tufts University School of Medicine.
Education includes doctorates from Vrije Universiteit Brussel and Harvard Medical School.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ANNOVIS BIO INC 0,05% | 04-09-2026 | 20.851 ( 0,05% ) | 35 864 $ | 31-08-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| ANNOVIS BIO, INC. | Directeur/Bestuurslid | 01-01-2015 |
SapVax LLC
SapVax LLC Pharmaceuticals: MajorHealth Technology Develops cancer vaccines based on a novel self-adjuvanting peptide platform technology for immuno-oncology applications | Hoofd Techniek/Wetenschap/O&O | - |
Ophidion, Inc.
Ophidion, Inc. BiotechnologyHealth Technology Engages in research and development of therapeutics for cognitive impairment diseases | Directeur/Bestuurslid | - |
| Bedrijven | Functie | Einde |
|---|---|---|
| NAVIDEA BIOPHARMACEUTICALS, INC. | Directeur/Bestuurslid | 14-09-2021 |
Center of Excellence For External Drug Discovery | Corporate Officer/Principal | 01-01-2008 |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Corporate Officer/Principal | - |
University of Pennsylvania
University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Tufts University School of Medicine
Tufts University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 11 |
|---|---|
Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc. Medical SpecialtiesHealth Technology Develops and commercializes precision diagnostics and radiopharmaceutical agents | Health Technology |
Annovis Bio, Inc.
Annovis Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for Alzheimer's and Parkinson's diseases and other neurodegenerative disorders | Health Technology |
University of Pennsylvania
University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vrije Universiteit Brussel
Vrije Universiteit Brussel Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Medical School
Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Health Technology |
Tufts University School of Medicine
Tufts University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
SapVax LLC
SapVax LLC Pharmaceuticals: MajorHealth Technology Develops cancer vaccines based on a novel self-adjuvanting peptide platform technology for immuno-oncology applications | Health Technology |
Prolifagen LLC
Prolifagen LLC BiotechnologyHealth Technology Develops ribonucleic acid therapeutics intended for cardiac tissue regeneration | Health Technology |
Center of Excellence For External Drug Discovery | |
Ophidion, Inc.
Ophidion, Inc. BiotechnologyHealth Technology Engages in research and development of therapeutics for cognitive impairment diseases | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau